Kane Biotech Inc. (KNBIF)
| Market Cap | 3.71M -23.2% |
| Revenue (ttm) | 27.27K -97.9% |
| Net Income | -1.90M |
| EPS | -0.01 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,000 |
| Open | 0.0200 |
| Previous Close | 0.0167 |
| Day's Range | 0.0186 - 0.0200 |
| 52-Week Range | 0.0104 - 0.0338 |
| Beta | 0.31 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 27, 2026 |
About Kane Biotech
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, a biofilm destabilizing formula with continuous activity; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine (PNAG) for treating wounds and otic infections. Its wound care product portfolio inclu... [Read more]
News
Kane Biotech Announces Second Quarter 2026 Financial Results
WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results.
Kane Biotech Earnings release: Q2 2026
Kane Biotech released its Q2 2026 earnings on August 27, 2026, summarizing the period's financial results.
Kane Biotech Registration statement: Q2 2026
Kane Biotech filed a registration statement on August 27, 2026, providing details about a securities offering with the SEC.
Kane Biotech Registration statement: Q2 2026
Kane Biotech filed a registration statement on August 27, 2026, providing details about a securities offering with the SEC.
Kane Biotech Announces Engagement of DNA Advisors
DNA Advisors brings expertise in capital markets, strategic transactions, partnerships, and growth initiatives DNA Advisors brings expertise in capital markets, strategic transactions, partnerships, a...
Kane Biotech Announces Results of Annual and Special Meeting of Shareholders
WINNIPEG, Manitoba, July 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) the voting results from its annual and special meeting of shareholders (th...
Kane Biotech Announces Grant of Stock Options
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, May 29, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the ...
Kane Biotech Announces First Quarter 2026 Financial Results
WINNIPEG, Manitoba, May 28, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its first quarter 2026 financial results.
Kane Biotech Registration statement: Q1 2026
Kane Biotech filed a registration statement on May 28, 2026, providing details about a securities offering with the SEC.
Kane Biotech Registration statement: Q1 2026
Kane Biotech filed a registration statement on May 28, 2026, providing details about a securities offering with the SEC.
Kane Biotech Earnings release: Q1 2026
Kane Biotech released its Q1 2026 earnings on May 28, 2026, summarizing the period's financial results.
Kane Biotech Slides: Investor presentation
Kane Biotech has posted slides in relation to its latest quarterly earnings report, which was published on May 28, 2026.
Kane Biotech Announces the Oversubscription and Closing of Private Placement Offering
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, May 26, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane...
Kane Biotech Presents Data To Global Wound Care Community at WCET®–NSWOCC® 2026 Joint Congress
Case study presented highlighted clinical experience with revyve® in complex wound care Case study presented highlighted clinical experience with revyve® in complex wound care
Kane Biotech Announces New Private Placement Offering
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, May 07, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the ...
Kane Biotech Announces Fourth Quarter and Full Year 2025 Financial Results
WINNIPEG, Manitoba, April 23, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its fourth quarter and full year 2025 financial results.
Kane Biotech Earnings release: Q4 2025
Kane Biotech released its Q4 2025 earnings on April 23, 2026, summarizing the period's financial results.
Kane Biotech Registration statement: Q4 2025
Kane Biotech filed a registration statement on April 23, 2026, providing details about a securities offering with the SEC.
Kane Biotech Registration statement: Q4 2025
Kane Biotech filed a registration statement on April 23, 2026, providing details about a securities offering with the SEC.
Kane Biotech Announces Publication in Frontiers in Antibiotics Highlighting Advancements in Treating Antibiotic Tolerant Biofilms
WINNIPEG, Manitoba, March 17, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or “Kane”) announces that Frontiers in Antibiotics has published a peer-reviewed article authored b...
Kane Biotech Expands U.S. Commercial Footprint with Strategic Distribution Partnership
WINNIPEG, Manitoba, March 10, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (Kane or the Company), transforming wound care with three FDA 510(k) cleared and two Health Canada approved formats, is pleased...
Kane Biotech Slides: Investor presentation
Kane Biotech has posted slides in relation to its latest quarterly earnings report, which was published on February 25, 2026.
Kane Biotech Announces Publication of revyve® Wound Gel Article in the International Wound Journal
WINNIPEG, Manitoba, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE) (“Kane Biotech” or “Kane”) announces the publication of an article on its revyve® Antimicrobial wound gel in the In...
Kane Biotech Expands Commercial Activities in the United States
WINNIPEG, Manitoba, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or the “Company”) today announces that it has signed non-exclusive distribution/sales agreements for...
Kane Biotech Announces FDA 510(k) Clearance for revyve® Antimicrobial Skin and Wound Cleanser
Company expands ISO 13485/MDSAP Certification to support growing wound care portfolio Company expands ISO 13485/MDSAP Certification to support growing wound care portfolio